COVID-19: NPPA asks states, UTs to ensure unobstructed movement of stock, manpower

Image
Press Trust of India New Delhi
Last Updated : Mar 27 2020 | 11:58 AM IST

The National Pharmaceutical Pricing Authority (NPPA) has asked all states as well as union territories to ensure seamless movement of stock and manpower of pharma companies amid coronavirus-induced lockdown across the country.

In a letter to the Chief Secretaries of all states and union territories (UTs), NPPA chairperson Shubhra Singh has asked them to ensure unobstructed movement of raw material, packing material, finished products and manpower related tomanufacturing and distribution of drugs and medical devices.

Referring to theguidelines issued by the home ministry to take effective measuresto prevent the spread of COVID-19 in the country, it said that while industrial establishments were to remain closed, exception was made for manufacturing units of essential goods, including drugs, pharmaceuticals, medical devices, raw materials and intermediates.

The letter has asked them (states and UTs) to pass instructions to the districtadministration /concerned authorities to facilitate the pharma companies and ensure smooth movement of stock and manpower during the lockdown period.

While as per the guidelines, all transport services will remain suspended exceptions were made for transportation of essential goods only.Exception was also made for petroleum products, LPG, food products and medical supplies, the letter said.

"The seamless functioning of pharma manufacturing and distribution units, both in public and private sector is essentialin dealing with the emergent situation. It is learnt that pharma companies are facing problem in movement of stock and manpower,which may hamper production and supply of medicines and medical devices thereby impacting their availability in the market," it added.

The letter also enclosed the representation received from industry body FICCI in this regard.

In the letter Singh said NPPA is also operating a control room with a helpline number and complaints received on the number are also being referred to state drug controller for suitable intervention.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 27 2020 | 11:58 AM IST

Next Story